Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Context Therapeutics stock
Learn how to easily invest in Context Therapeutics stock.
Context Therapeutics is a biotechnology business based in the US. Context Therapeutics shares (CNTX) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy Context Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – CNTX. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Context Therapeutics stock price (NASDAQ: CNTX)Use our graph to track the performance of CNTX stocks over time.
Context Therapeutics shares at a glance
|Latest market close||$0.73|
|52-week range||$0.60 - $2.79|
|50-day moving average||$0.96|
|200-day moving average||$1.52|
|Wall St. target price||N/A|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.93|
Buy Context Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Context Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Context Therapeutics price performance over time
|1 week (2023-01-20)||5.19%|
|1 month (2022-12-27)||9.94%|
|3 months (2022-10-27)||-45.11%|
|6 months (2022-07-27)||-62.18%|
|1 year (2022-01-27)||-62.56%|
|2 years (2021-01-27)||-99.62%|
|3 years (2020-01-24)||330|
|5 years (2018-01-23)||N/A|
Context Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-39.72%|
|Return on equity TTM||-80.2%|
|Market capitalisation||$11.1 million|
TTM: trailing 12 months
Context Therapeutics share dividends
We're not expecting Context Therapeutics to pay a dividend over the next 12 months.
Context Therapeutics overview
Context Therapeutics Inc. , a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc.
Context Therapeutics in the news
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
Frequently asked questionsWhat percentage of Context Therapeutics is owned by insiders or institutions?
Currently 5.821% of Context Therapeutics shares are held by insiders and 29.477% by institutions. When does the fiscal year end for Context Therapeutics?
Context Therapeutics's fiscal year ends in December. Where is Context Therapeutics based?
Context Therapeutics's address is: 2001 Market Street, Philadelphia, PA, United States, 19103 What is Context Therapeutics's ISIN number?
Context Therapeutics's international securities identification number is: US21077P1084
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert